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INTRODUCTION 
Systemic lupus erythematosus (SLE) is a multi-
systemic autoimmune disease associated with 
significant morbidity and mortality in both adults1 
and children2,3. Compared to adults, paediatric SLE 
patients have an increased incidence (up to 82%) 
and severity of lupus nephritis (LN)4,5, which 
determines both the renal and overall prognosis6.  
 
EPIDEMIOLOGY 
The prevalence of SLE is 1 case in 2000 in the 
general population. Because of the difficulty in 
diagnosis and a probable underestimation of SLE 
cases, researchers suggest that the prevalence may 
be closer to 1 case in 500-1000 population7. 
Histologically, the kidneys are affected to some 
degree in most patients with SLE. Estimates of the 
prevalence of clinical renal involvement in persons 
with SLE range between 30 and 90% in published 
studies. Most patients develop nephritis early in 
their disease evolution8. Lupus nephritis is more 
common in females because the overall prevalence 
of SLE is higher in females (i.e., female-to-male 
ratio of 4-1 prepubertal and 9:1 postpubertal); 
however, males with SLE have an increased 
prevalence of clinical renal disease with a worse 
prognosis. Asians, African-Caribbeans and African-




HLA antigens have been associated with an 
increased risk of developing nephritis and the HLA-
DR2 and HLA-B8 are more associated with the 
development of lupus renal disease than inheritance 
of the HLA-DR4 gene10,11. Polymorphisms of Fc 
receptors for IgG (FcgammaR) were recently 
identified as a risk factor, implicating defective 
handling of circulating immune complexes in the 
development of renal disease12.  
 
IMMUNOPATHOGENESIS 
At least three potentially overlapping, immuno-
pathogenic mechanisms are supported by 
experimental data. First, circulating immune 
complexes consisting chiefly of DNA and anti-
DNA are deposited in the kidney. Resulting 
complement activation and chemotaxis of 
neutrophils leads to a local inflammatory process. 
Second, in situ formation of antigen and antibody 
complexes may similarly lead to complement 
activation and leucocyte mediated injury. Third, 
antibodies against specific cellular targets may 
produce renal injury. For example, antibodies, such 
as anti-ribosomal P, may bind to cytoplasmic 
antigens that have been translocated to the cell 
membrane with subsequent penetration and 
disruption of cellular function13.  
An additional mechanism is observed in SLE 
patients with the antiphospholipid antibody 
syndrome. Glomerular thrombosis can result from 
the hypercoagulability that accompanies antibodies 
directed against negatively charged phospholipid-
protein complexes (e.g. biologic false positive 




Active lupus renal disease can be defined clinically 
or pathologically. Clinically the symptoms are 
generally related to hypertension, proteinuria, and 
renal failure. The disease is evaluated by urinalysis, 
24 hour urine protein and creatinine excretion or 
protein/creatinine ratio in spot sample, serum 
creatinine, anti-DNA titers, and serum complement. 
Additionally, serum albumin and cholesterol can be 
used to help characterize the nature of lupus renal 
disease15.  
Unfortunately, obtaining an accurate 
measurement of the glomerular filtration rate is not 
easy. Taking inulin clearance as the 'gold standard', 
Shemesh et al. 198516 had demonstrated that 
creatinine clearance determinations overestimate 
the glomerular filtration rate during the acute phase 
of lupus nephritis, probably as a result of tubular 
secretion of creatinine. Isotopic tests (e.g. 99Tc-
DTPA) appear to provide a more accurate measure 
of glomerular filtration rate in these patients. 
The urinary sediment is useful to characterize 
disease activity as the presence of leukocyturia, 
hematuria or hyaline casts (in descending order) are 
typical only during periods of disease activity. A 
rising anti-DNA titer and hypocomplementemia, 
especially with low C3, are strong indicators or 
predictors of active lupus renal disease17. ESR is 
usually elevated during active nephritis. Clinically 
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relevant lupus nephritis is associated with a 30% 
decrease in creatinine clearance, proteinuria of 
greater than 1000 mg/dl18. 
Confusing clinical management is the 
phenomenon of fixed proteinuria. There are patients 
who do not have active immunologic injury who 
have persistent proteinuria. It is hypothesized that 
the prior immunologic injury and remitted 
inflammatory process create dysfunctional 
glomeruli incapable of preventing protein excretion. 
Therefore, patients may excrete 1-3 grams per day 
of protein even during periods of disease 
remission19.  
Hypoalbuminemia accompanied by significant 
proteinuria is a component of the nephrotic 
syndrome which may accompany active lupus renal 
disease. Hypercholesterolemia is another marker 
and clinical complication of the nephrotic syndrome 
that can accompany active lupus renal disease. 
Tubular damage, fibrosis and atrophy can be 




• Complete remission (CR) was defined as the 
presence of all of the following three criteria for 
at least 6 months: serum creatinine <1.2 mg/dl, 
absence of proteinuria (negative or trace on the 
urine stick and 24 h or spot urine/creatinine ratio 
<0.2), and inactive urinary microscopic sediments 
[absence of cellular casts and <10 red blood cells 
per high-power-field) (RBCs/HPF)].  
• Partial remission (PR) was defined as 
improvement or stabilization of a previously 
elevated serum creatinine level, improvement in a 
previously elevated proteinuria reduced to a non-
nephrotic range (24 h or spot urine 
protein/creatinine ratio ≤3.0) for at least 
6 months, and the presence or absence of 
hematuria or RBC casts.  
• No remission (NR) was defined as a persistent 
nephrotic-range of proteinuria (24 h or spot urine 
protein/creatinine ratio >3.0) regardless of the 
presence of urinary sediment, and/or no 
improvement in abnormal serum creatinine 
concentration.  
• An initial response was defined as achieving a 
first CR or PR without the new appearance of 
proteinuria, hematuria, or increased serum 
creatinine for at least 6 months.  
• Renal flares could be classified as being either 
proteinuric or nephritic. Proteinuric flare was 
characterized by the reappearance of nephrotic-
range proteinuria (24 h or spot urine 
protein/creatinine ratio >3.0) with a stable serum 
creatinine level. Nephritic flare was defined as an 
increase in serum creatinine to 1.4 mg/dl or above 
(double-checked), or an increase in the last value 
by at least 50%, which is generally associated 
with active urinary sediment (RBC >10/HPF or 
cellular casts) and an increased quantity of 
proteinuria.  
Lupus renal disease is also defined 
pathologically. Histological evidence of lupus 
nephritis is present in most patients with SLE, even 
if they do not have clinical manifestations of renal 
disease. Several studies have illustrated the lack of 
reliability of diagnoses rendered on the basis of 
clinical features alone22. Therefore, making a 
diagnosis on clinical grounds alone is problematic 
and risky, underscoring the need for kidney biopsy. 
With diverse renal histopathological findings 
possible in SLE-affected patients, biopsy 
determines not only the diagnosis and prognosis, 
but also substantially guides management of this 
complex disease. As the therapeutic armamentarium 
for lupus nephritis expands, it becomes even more 
imperative that the correct diagnosis be made prior 
to instituting therapy. In deciding whether to 
perform a biopsy, one must balance the risks of the 
biopsy procedure against the risks of limited 
diagnostic information, which may result in 
progression of potentially preventable renal disease 
or the unnecessary use of a possibly toxic therapy.  
 Material obtained by renal biopsy is evaluated by 
light microscopy, immunofluorescence and electron 
microscopy. The first World Health Organization 
(WHO) classification was formulated by Pirani and 
Pollak in Buffalo, New York in 1974 and was first 
used in publications in 197523 and 197824. This 
classification addressed glomerular lesions only. 
Class I was applied to renal biopsies showing no 
detectable glomerular abnormalities by light, 
fluorescence, or electron microscopy. Class II was 
defined as purely mesangial immune deposition and 
was subdivided into two subclasses depending on 
whether mesangial hypercellularity was present. 
Class III lesions were defined as proliferative 
glomerulonephritis affecting fewer than 50% of the 
glomeruli (i.e., focal), whereas class IV was defined 
as proliferative glomerulonephritis affecting more 
than 50% of the glomeruli (i.e., diffuse). No 
qualitative differences between class III and class 
IV lesions were described. Membranous lupus 
nephritis was classified as class V. 
Tubulointerstitial and vascular lesions were not 
included in the classification system. In 1982, the 
WHO classification was modified by the 
International Study of Kidney Diseases in 




class III and IV based on the presence of active, 
chronic, or mixed types of glomerular injury. Class 




Table 1. World Health Organization (WHO) 
morphologic classification of lupus nephritis 
(modified in 1982) Quoted from (Geoffrey et al, 
2006)25. 
Class I Normal glomeruli 
  a. Nil (by all techniques) 
 b. Normal by light microscopy, but 
deposits by electron or immuno-
fluorescence microscopy 
Class II Pure mesangial alterations 
(mesangiopathy) 
  a. Mesangial widening and/or mild 
hypercellularity (+) 
 b. Moderate hypercellularity (++) 
Class III Focal segmental glomerulonephritis 
(associated with mild or moderate 
mesangial alterations) 
  a. With "active" necrotizing lesions 
 b. With "active" and sclerosing lesions 
 c. With sclerosing lesions 
Class IV Diffuse glomerulonephritis (severe 
mesangial, endocapillary or mesangio-
capillary proliferation and/or extensive 
subendothelial deposits) 
  a. Without segmental lesions 
 b. With "active" necrotizing lesions 
 c. With "active" and sclerosing lesions 
 d. With sclerosing lesions 
Class V Diffuse membranous 
glomerulonephritis 
  a. Pure membranous glomerulonephritis 
 b. Associated with lesions of class II 
 c. Associated with lesions of class III 
 d. Associated with lesions of class IV 




More recently the National Institutes of Health 
(NIH) developed activity and chronicity indices 
(Table 2)26. High chronicity scores are associated 
with poor outcome and a lack of response to 
immunosuppression. High activity indices are 
associated with poor outcomes, but may be 
reversible, especially with aggressive treatment27. 
There has been some concern regarding the 





Table 2. NIH renal pathology system26.  
Activity Index Chronicity Index 
Glomerular abnormalities 
1. Cellular proliferation 1. Glomerular sclerosis 
2. Fibrinoid necrosis, 
karyorrhexis 2. Fibrous crescents 
3. Cellular crescents  
4. Hyaline thrombi, wire loops  
5. Leukocyte infiltration  
Tubulointerstitial abnormalities 
1. Mononuclear cell infiltrates 1. Interstitial fibrosis 
 2. Tubular atrophy 
Severity of each index quantitated as 0 = absent, 1 = mild, 2 = 
moderate, and 3 = severe. Fibrinoid necrosis and cellular 
crescents are weighted by a factor of 2. Maximum activity 
index is 24 and that of chronicity index 12. 
 
In 2003, the International Society of 
Nephrology and Renal Pathology Society 
(ISN/RPS) advised a new classification of lupus 
nephritis (Table 3 and figures 1-12)29. Overall, it 
bears a strong similarity to the 1974 classification, 
but introduces several important modifications 
concerning quantitative and qualitative differences 
between class III and IV lesions. This new 
classification provides a clear and unequivocal 
description of the various lesions and classes of LN, 
removing the ambiguity of the WHO classification 
and allowing overlap cases between two classes to 
be documented accurately. It was strongly 
recommended that any significant vascular and 
tubulointerstitial pathology to be reported as 
separate entries in the diagnostic line.  
 
 
Table 3. International Society of Nephrology/Renal 
Pathology Society (ISN/RPS) 2003 classification of 
lupus nephritis29. 
Class I Minimal mesangial lupus nephritis 
 Normal glomeruli by light microscopy, but 
mesangial immune deposits by 
immunofluorescence 
Class II Mesangial proliferative lupus nephritis 
 Purely mesangial hypercellularity of any 
degree or mesangial matrix expansion by 
light microscopy, with mesangial immune 
deposits 
May be a few isolated subepithelial or 
subendothelial deposits visible by 
immunofluorescence or electron microscopy, 
but not by light microscopy 
Class III Focal lupus nephritis a 
 Active or inactive focal, segmental or global 
endo- or extracapillary glomerulonephritis 
involving <50% of all glomeruli, typically 
with focal subendothelial immune deposits, 
Childhood lupus nephritis 
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with or without mesangial alterations 
Class III 
(A) 




Active and chronic lesions: focal 
proliferative and sclerosing lupus nephritis 
Class III 
(C) 
Chronic inactive lesions with glomerular 
scars: focal sclerosing lupus nephritis 
Class IV Diffuse lupus nephritis b 
 Active or inactive diffuse, segmental or 
global endo- or extracapillary 
glomerulonephritis involving 50% of all 
glomeruli, typically with diffuse 
subendothelial immune deposits, with or 
without mesangial alterations. This class is 
divided into diffuse segmental (IV-S) lupus 
nephritis when 50% of the involved 
glomeruli have segmental lesions, and 
diffuse global (IV-G) lupus nephritis when 
50% of the involved glomeruli have global 
lesions. Segmental is defined as a glomerular 
lesion that involves less than half of the 
glomerular tuft. This class includes cases 
with diffuse wire loop deposits but with little 
or no glomerular proliferation 
Class IV-S 
(A) 
Active lesions: diffuse segmental 
proliferative lupus nephritis 
Class IV-
G (A) 




Active and chronic lesions: diffuse 
segmental proliferative and sclerosing lupus 
nephritis 
 Active and chronic lesions: diffuse global 
proliferative and sclerosing lupus nephritis 
Class IV-S 
(C) 
Chronic inactive lesions with scars: diffuse 
segmental sclerosing lupus nephritis 
Class IV-
G (C) 
Chronic inactive lesions with scars: diffuse 
global sclerosing lupus nephritis 
Class V Membranous lupus nephritis 
 Global or segmental subepithelial immune 
deposits or their morphologic sequelae by 
light microscopy and by 
immunofluorescence or electron microscopy, 
with or without mesangial alterations 
 Class V lupus nephritis may occur in 
combination with class III or IV in which 
case both will be diagnosed 
 Class V lupus nephritis show advanced 
sclerosis 
Class VI Advanced sclerosis lupus nephritis 
 90% of glomeruli globally sclerosed without 
residual activity 
a Indicate the proportion of glomeruli with active and with 
sclerotic lesions.  
b Indicate the proportion of glomeruli with fibrinoid necrosis 
and/or cellular crescents.  
Indicate and grade (mild, moderate, severe) tubular atrophy, 
interstitial inflammation and fibrosis, severity of 






The distribution and quantity of electron dense 
deposits, a surrogate on electron microscopy for 
immune complexes, are also of prognostic and 
therapeutic significance30. Class I and Class IV 
disease are associated with mesangial and 
subepithelial location of electron dense deposits, 
respectively. Proliferative nephritis, both Class III 
and IV, are both associated with subendothelial 
deposits.  
Although clearly not without exception, there is 
a correlation between the pathologic type of lupus 
renal disease and the aforementioned clinical 
features. Obviously, patients with normal renal 
biopsies have normal diagnostic and blood tests. 
Mesangial lupus nephritis is accompanied by 
normal diagnostic findings or with a mild degree of 
proteinuria but typically absence of hypertension or 
abnormal urinary sediment. Focal and diffuse 
proliferative lupus glomerulonephritis are often 
associated with the worst prognosis for renal 
survival and can be accompanied by nephrotic 
syndrome, significant hypertension and abnormal 
urine sediment. Membranous lupus nephritis often 
presents with proteinuria, moderate to high grade, 
but usually normal urinary sediment in the absence 
of hypertension31.  
It should be mentioned that in the contra-
positive there are patients with so-called silent 
lupus nephritis who have normal urinalyses, 
absence of proteinuria and normal serum creatinine 
but who, on renal biopsy, have anywhere from 
mesangial to proliferative nephritis32. Fortunately, it 
has not been demonstrated that progressive loss of 
renal function in these cases occurs silently, that is 
to say without the appearance of a perturbed urinary 
sediment and albuminuria.  
 
MANAGEMENT 
Goals of Therapy: Although there is no consensus 
on outcome definitions, such as remission and 
relapse of LN, most clinicians will agree on the 
following therapeutic goals for a patient with newly 
diagnosed lupus nephritis: (1) to achieve prompt 
renal remission, (2) to avoid renal flares, (3) to 
avoid chronic renal impairment, and (4) to fulfill 
these objectives with minimal toxicity33.  
Unmet Expectations: Although patient and renal 
survival rates have improved over the past decade, it 
should be stressed that current immunosuppressive 
regimens still achieve suboptimal results. First, the 
rate of renal remission after a first-line therapy is at 
best 81% in recent prospective studies33-37. Second, 
renal relapses occur in one third of LN patients38, 
mostly when patients are still immunosuppressed39. 




experience ESRD 5 to 10 yr after disease onset, 
although these figures are lower (between 5 and 
10%) in recent studies36,37,40. Finally, treatment-
related toxicity remains a major concern, such as 
metabolic and bone side effects of high-dose 
glucocorticoids (GC)41-43, severe infections, or 
premature ovarian failure in females who receive 
high-dose cyclophosphamide (CYC)44-45.  
• Therapies for renal biopsy–specific pathologic 
lesions46 
o Class I lesions require no specific therapy.  
o For class II lesions, treatment of extrarenal 
manifestations may be the only therapy 
required. If proteinuria is greater than 1000 
mg/d, elevated anti-dsDNA is present, and low 
complement levels are present, the patient could 
have a proliferative component not sampled in 
the biopsy specimen. Consider prednisone in 
low-to-moderate doses (i.e., 0.5-1 mg/kg/d) for 
1-3 months, with subsequent taper.  
o With class III and IV lesions, patients are at 
high risk of progressing to end-stage renal 
disease and require aggressive therapy.  
 Administer prednisone 1 mg/kg/d for at least 
4 weeks, depending on clinical response. 
Then, taper it gradually to a daily 
maintenance dose of 5-10 mg/d for 
approximately 2 years. In acutely ill patients, 
intravenous methylprednisolone for 3 days 
may be used to initiate corticosteroid therapy.  
 Use immunosuppressive drugs in addition to 
corticosteroids in patients who do not respond 
to corticosteroids alone, who have 
unacceptable toxicity to corticosteroids, who 
have worsening renal function, who have 
severe proliferative lesions, or who have 
evidence of sclerosis on renal biopsy 
specimens. Both cyclophosphamide 
(Evidence class B)47 and azathioprine 
(Evidence class B)48 are effective for 
proliferative lupus nephritis, although 
cyclophosphamide apparently is more 
effective in preventing progression to end-
stage renal disease. Mycophenolate mofetil 
has been shown to be effective in treating 
these patients and may be used sequentially 
after a 6-month course of intravenous 
cyclophosphamide (Evidence class B)49.  
 Administer intravenous cyclophosphamide 
monthly for 6 months as an induction and to 
control flares (Figure 13)50 and every 2-3 
months thereafter, as a maintenance therapy, 
depending on clinical response51. The usual 
duration of therapy is 2-2.5 years. Reduce the 
dose if the creatinine clearance is less than 30 
mL/min. Adjust the dose depending on the 
hematologic response.  
 Azathioprine can also be used as a second-
line agent, with dose adjustments depending 
on hematologic response.  
 Mycophenolate mofetil may be useful if the 
patient does not respond to or cannot tolerate 
cyclophosphamide and azathioprine. 
o For class V lesions, patients are generally 
treated with prednisone for 1-3 months, 
followed by tapering for 1-2 years if a response 
occurs or, if no response occurs, by 
discontinuation. Immunosuppressive drugs are 
generally not used unless worsening renal 
function or a proliferative component is present 
on renal biopsy samples. Some clinical 
evidence indicates that azathioprine, 
cyclophosphamide, chlorambucil, and 
cyclosporine are effective in reducing 
proteinuria. Mycophenolate mofetil may also be 
effective. 
• End-stage renal disease  
o Patients with end-stage renal disease need 
dialysis and are good candidates for kidney 
transplantation52.  
o Hemodialysis is preferred over peritoneal 
dialysis because several studies have 
documented higher anti-dsDNA levels, more 
thrombocytopenia, and higher steroid 
requirements in patients with SLE and end-
stage renal disease who are on peritoneal 
dialysis. Hemodialysis also has anti-
inflammatory effects with decreased T-helper 
lymphocyte levels. SLE is generally quiescent 
in patients on hemodialysis, although flares, 
including rash, arthritis, serositis, fever, and 
leukopenia, may occur and require specific 
treatment53. 
Intravenous immunoglobulins are increasingly 
being used in the treatment of resistant lupus, 
though there have been no large randomised trials. 
They also have a role in patients who have 
concomitant infection and active lupus, in whom 
immunosuppression is risky, and have been used in 
the treatment of many clinical manifestations in 
SLE54.  
 
Novel therapies  
There have been major advances in the treatment of 
SLE, especially with biological agents. Rituximab is 
a chimeric human-murine monoclonal antibody 
directed against CD-20 on B cells and their 
precursors but not against plasma cells. Rituximab 
is widely used in the management of lymphoma and 
is relatively safe and well tolerated. Several open 
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studies have shown dramatic and long lasting 
remissions after only two to four infusions in 
patients who were previously unresponsive to 
conventional and even novel immunosuppressive 
agents such as mycophenolate mofetil55. The 
optimum combination of rituximab with 
methylprednisolone and cyclophosphamide remains 
undefined.  
Specific agents that are undergoing clinical 
investigation include LJP397, which is known as a 
B cell tolerogen. This is a novel therapy consisting 
of four oligonucleotides attached to a triethylene 
glycol platform, which when infused, is bound by 
the Fab portion of anti-DNA antibodies in the 
membrane of auto-reactive B cells. Cross linking of 
anti-DNA antibody in the cell membrane of B cells 
results in a down regulation of anti-DNA 
immunoglobulin synthesis and apoptosis of these B 
cells. In animal models of lupus renal disease, this 
approach has not only reduced the production of 
anti-DNA, but mitigated renal disease. Human 
studies have suggested that this is a non-toxic 
therapy and in 1997 a multicenter randomized 
double blind study investigating its efficacy was 
initiated56.  
Additional agents that may have a role in the 
treatment of lupus nephritis include a monoclonal 
antibody to the fifth component of complement. 
The monoclonal anti-C5 reduces the production of 
C5a and C5b-9 and the inflammatory reaction 
which appears consequent to the generation of 
immune complexes in the kidney57. An additional 
agent, anti-CD40ligand monoclonal antibody, has 
the ability to reduce the production of auto-
antibodies. Anti-CD40ligand not only inhibits 
production of pathogenic antibodies but can inhibit 
inflammatory cytokine production and T cell 
dependent activation of endothelial cells58.  
Clinical trials are currently assessing the 
potential of various peptides and biological agents 
such as abatacept (CTLA4 Ig)59 and epratuzmab60 in 
lupus. To date no medications of any class have 
ever been officially licensed for use in lupus, and 
these trials offer hope that several agents may be 
registered specifically for lupus patients. 
 
Adjuvant Management61 
o Treatment of hypertension aggressively. To 
consider ACE inhibitors if the patient has 
significant proteinuria, unless significant renal 
insufficiency is present.  
o Restriction of fat intake for hyperlipidemia 
secondary to nephrotic syndrome.  
o Restriction of protein intake if renal function is 
significantly impaired.  
o Administration of calcium supplementation to 
prevent osteoporosis if the patient is on long-term 
corticosteroid therapy, and to consider adding a 
bisphosphonate.  
o Avoidance of drugs that affect renal function, 
including nonsteroidal anti-inflammatory drugs, 
especially in patients with elevated creatinine 
levels.  
o Patients should avoid pregnancy if they have 
active lupus nephritis because it may worsen their 
renal disease.  
o Patients with end-stage renal disease, sclerosis, 
and a high chronicity index based on renal biopsy 
findings are unlikely to respond to aggressive 
therapy. In these cases, focus therapy on 




Numerous prognostic factors have been 
identified61,62. Among others, nonwhite race (e.g., 
black, Afro-Caribbean, Hispanic), poor 
socioeconomic status, uncontrolled hypertension, a 
high activity and chronicity index on kidney biopsy, 
renal impairment at baseline, poor initial response 
to therapy, and nephritic relapses have been 
associated with poor outcome. Lack of compliance 
to therapy, in particular to high-dose oral GC, is a 
trivial but underestimated (and mostly 
unconfessed!) cause of treatment failure. In a few 
cases, unrecognized association of proliferative LN 
with a thrombotic microangiopathy linked to the 
antiphospholipid clotting syndrome may further 
worsen the prognosis63.  
Taken together, LN still has a negative impact on 
lupus patients’ survival as indicated by the long-
term data collected between 1990 and 2000 by the 
investigators of the European Working Party on 
Systemic Lupus Erythematosus in a prospective 
series of 1000 European patients, whose overall 
survival rate at 10 yr was 88 and 94% for patients 








Figures 1-6.  (1) Lupus nephritis class II. Light 
micrograph of a glomerulus with mild mesangial 
hypercellularity [periodic acid-Schiff (PAS)]. (2) Lupus 
nephritis class III (A). Light micrograph showing a 
glomerulus with segmental endocapillary 
hypercellularity, mesangial hypercellularity, capillary 
wall thickening, and early segmental capillary necrosis 
(methenamine silver). (3) Lupus nephritis class III (A). 
Light micrograph showing a glomerulus with segmental 
capillary necrosis with sparing of the remainder of the 
capillary tuft—a vasculitis-like lesion (methenamine 
silver). (4) Lupus nephritis class IV-G (A). Light 
micrograph showing a glomerulus with global 
involvement of endocapillary and mesangial 
hypercellularity and matrix expansion, influx of 
leukocytes, and occasional double contours 
(methenamine silver). (5) Lupus nephritis class IV-S (A). 
Segment of a glomerulus showing endocapillary 
hypercellularity, capillary wall double contours, wireloop 
lesions, and hyaline thrombi (PAS). (6) Lupus nephritis 
class IV-G (A/C). Light micrograph of a glomerulus 
showing global severe endo- and extracapillary 
proliferation, wireloop lesions, leukocyte influx, 
apoptotic bodies, capillary necrosis, and mesangial 
expansion with hypercellularity and matrix expansion; 
marked interstitial inflammatory infiltration (PAS)  
[Quoted from Weening et al, 2004]29. 
 
Figures 7-12. (7) Lupus nephritis class IV-G (A/C). 
Glomerulus with global endocapillary proliferation, leukocyte 
influx and apoptotic bodies, double contours, crescent 
formation with tubular transformation, early sclerosis, and 
disruption of Bowman’s capsule (PASd). (8) Lupus nephritis 
class IV-G (A). Glomerulus with widespread subendothelial 
immune deposits (wireloop lesions) associated with basement 
membrane new formation along the inner side of the 
capillaries but without endocapillary leukocyte infiltration or 
hypercellularity (methenamine silver). (9) Lupus nephritis 
class V. Glomerulus with advanced-stage lupus membranous 
nephropathy characterized by massive subepithelial 
accumulation of immune deposits (immunofluorescence: full 
house) and interdigitating spike formation (methenamine 
silver). (10) Lupus nephritis class IV and V (A/C). 
Glomerulus with lupus membranous nephropathy with 
subepithelial spike formation combined with global 
endocapillary and mesangial hypercellularity, early crescent 
formation, and beginning mesangial and capillary sclerosis 
(methenamine silver). (11) Lupus nephritis class VI. Renal 
cortex showing almost diffuse, global glomerular sclerosis 
accompanied by interstitial fibrosis, mononuclear 
inflammatory infiltrates, and vascular sclerosis (methenamine 
silver). (12) Thrombotic microangiopathy in a patient with 
SLE and circulating anticoagulans. A glomerulus showing 
severe capillary and arteriolar thrombosis, endothelial cell 
swelling and necrosis, neutrophil influx, and stasis of 
erythrocytes. No signs of immune deposits (methenamine 
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MP, methylprednisone; IVIg, intravenous immunoglobulins; MMF, mycophenolate mofetil 
Figure 13. Proposed therapeutic options in patients with lupus nephritis and severe renal involvement at 
presentation or at renal flares. In patients with normal renal function, the treatment of induction or flares may 
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